Cargando…

Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis

BACKGROUND: Aim of the present study was to identify the predictors of ibandronate efficacy in subjects with osteoporosis or decreased bone mineral density (BMD). METHOD: Several electronic databases were searched by using specific keywords for the acquisition of research articles reporting the effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Zeren, Li, Yong, Zhou, Ming, Huang, Kedi, Hu, Hejun, Liu, Xiaoping, Xu, Xiaosheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773099/ https://www.ncbi.nlm.nih.gov/pubmed/26930292 http://dx.doi.org/10.1371/journal.pone.0150203

Ejemplares similares

Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis
por: Hou, Yanjie, et al.
Publicado: (2015)

Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis
por: Inderjeeth, Charles A, et al.
Publicado: (2014)

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis
por: Nakamura, T., et al.
Publicado: (2015)

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
por: Sambrook, Philip
Publicado: (2007)

Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2018)

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis
por: Bauss, Frieder, et al.
Publicado: (2006)

A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis
por: Horikawa, Akira, et al.
Publicado: (2019)

Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis
por: Ono, Yuichi, et al.
Publicado: (2018)

Effect of lumbar spinal stenosis on bone mineral density in osteoporosis patients treated with ibandronate
por: Park, Hyung-Youl, et al.
Publicado: (2021)

Efficacy and Safety of Monthly 150 mg Oral Ibandronate in Women with Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Lee, Young Ho, et al.
Publicado: (2011)

The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
por: Nakai, Kiyohiko, et al.
Publicado: (2014)

Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis
por: Cho, In-Jin, et al.
Publicado: (2015)

Effects of ibandronate-hydroxyapatite on resorptive activity of osteoclasts
por: Zhang, Xiaohui, et al.
Publicado: (2011)

Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis
por: Lotz, Ethan M., et al.
Publicado: (2019)

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2021)

Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis
por: Takeuchi, Yasuhiro, et al.
Publicado: (2018)

Treatment of Polyostotic Fibrous Dysplasia With Intravenous Ibandronate
por: Kazi, Fatima M, et al.
Publicado: (2021)

Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
por: Tanaka, Mizue, et al.
Publicado: (2017)

Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis
por: Ma, Zeren, et al.
Publicado: (2017)

Chinese herbal medicine Yanghe decoction for ankylosing spondylitis: A protocol for systematic review and meta-analysis
por: Xu, Xiaosheng, et al.
Publicado: (2020)

Use of ibandronate in the prevention of skeletal events in metastatic breast cancer
por: Devitt, Bianca, et al.
Publicado: (2008)

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.
por: Ralston, S. H., et al.
Publicado: (1997)

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
por: Derman, Richard, et al.
Publicado: (2009)

Ibandronate: The loading dose concept in the treatment of metastatic bone pain
por: Maier, Gerrit Steffen, et al.
Publicado: (2015)

Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model
por: Chung, Yoon-Sok, et al.
Publicado: (2015)

Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis
por: Nakamura, Toshitaka, et al.
Publicado: (2013)

Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
por: Hagino, Hiroshi, et al.
Publicado: (2014)

Local Application of Ibandronate/Gelatin Sponge Improves Osteotomy Healing in Rabbits
por: Yang, Zongyou, et al.
Publicado: (2015)

Preparation and Properties of New Co-Crystals of Ibandronate with Gluco- or Galactopyranoside Derivatives †
por: Oktabec, Zbynek, et al.
Publicado: (2010)

Farnesyl pyrophosphate synthase inhibitor, ibandronate, improves endothelial function in spontaneously hypertensive rats
por: HAN, JIE, et al.
Publicado: (2016)

Chinese herbal medicine Yanghe decoction for knee osteoarthritis: A protocol for systematic review and meta-analysis
por: Xu, Xiaosheng, et al.
Publicado: (2020)

Osteoprotegerin genetic polymorphisms and their influence on therapeutic response to ibandronate in postmenopausal osteoporotic females
por: Tariq, Saba, et al.
Publicado: (2023)

Ibandronate promotes autophagy by inhibiting Rac1–mTOR signaling pathway in vitro and in vivo
por: Han, Jie, et al.
Publicado: (2022)

Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases
por: Wang, Gengshen, et al.
Publicado: (2018)

Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells
por: Thaler, R., et al.
Publicado: (2013)

Administration of bisphosphonate (ibandronate) impedes molar tooth movement in rabbits: A radiographic assessment
por: Venkataramana, V., et al.
Publicado: (2014)

The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta
por: Ipach, Ingmar, et al.
Publicado: (2012)

Local application of an ibandronate/collagen sponge improves femoral fracture healing in ovariectomized rats
por: Guo, Jialiang, et al.
Publicado: (2017)

Denosumab/ibandronic acid/zoledronic acid: Medication-related osteonecrosis of jaw: case report
Publicado: (2021)

Efficacy of Jintiange Capsules in the Treatment of Osteoporosis: A Network Meta‐analysis
por: Sun, Jing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_or6e0h0ol1589ss6l9cqd56in3